Theme: Revolutionary Essence of Motivating the Living and Good Health of Women

Gynecologic Oncology 2017

Gynecologic Oncology 2017

3rd World Gynecologic Oncology Congress

Dates   : June 29-30, 2017

Venue  : Baltimore, USA

Theme : Revolutionary Essence of Motivating the Living and good health of Women


Conferenceseries LLC invites all the participants across the globe to attend the "3rd World Gynecologic Oncology Congress”slated on June  29-30, 2017 Baltimore, USA.

Global Gynecology Oncology conferences provides two day of robust discussions on methods and strategies related to management and quality improvement of Cancer therapy as well as explore new ideas and concepts on a global scale and topics include ovarian cancer, Breast cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer.

Nearly 80,000 women are diagnosed with Oncology Gynecology in the United States, and half of those are uterine cancer diagnoses with a mortality of 8,000 women per year. Ovarian cancer found to be the 2nd most common Oncology Gynecology with about 22,000 new cases per year, leading to 16,000 deaths yearly. Mortality for cervical cancer have decreased as Pap smears have become commonplace. Still, there are about 12,000 diagnoses every year with about 4,200 women die from this disease annually. Vulvar and vaginal cancer are relatively rare and when caught and treated early offers of reasonably good prognosis. 4,500 women are diagnosed with vulvar cancer each year, with about 950 women die from it. Vaginal cancer, meanwhile, account for about 2,600 diagnoses per year, and about 840 deaths. Every woman is at risk for developing a Oncology Gynecology. It is estimated that there will be about 98,000 new cases diagnosed and approximately 30,000 deaths from Oncology Gynecology in the United States during 2015 as per American Cancer Society. Out of which Uterine cancer has the large portion about 50% of cases with an estimated mortality rate of 18.5%. The Ovarian cancer has the highest estimated mortality rate at 66%.

OMICS International along with itssubsidiary Conference Series LLC  which is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse Medical(Cancer meeting,cancer conferencesoncology societyEuropean oncology conferencessurgical oncology,global cancer conferencecancer conferencesAmerican oncology society), Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe.

Why to attend ?

With members from around the world focused on learning about Oncology Gynecology; this is your best opportunity to reach the largest assemblage of participants from the Gynecologists community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Oncology Gynecology are hallmarks of this conference.

Speakers will include world renowned experts in all disciplines, offering a unique opportunity to highlight new technologies in all aspects of breast healthcare.

The congress program includes speakers who are the world’s leading Gynecology & breast healthcare specialists.

·         Networking opportunities.

·         Welcome Reception to mingle with speakers and society leadership.

·         Meet the Expert Sessions.

·         Relationship building opportunities throughout the congress.

·         Educational sessions and special events.

·         Professional Trade Exhibition.

·         Morning and afternoon refreshment breaks

Target Audience

·         Oncologists

·         Radiologists

·         Scientists

·         Surgeons

·         Pathologists

·         Researchers

·         Faculty

·         Students

·         Allied Health Professionals

·         Oncology Gynecology Associations and Societies

·         Business Entrepreneurs

·         Software Developing Companies

·         Medical Devices Companies

·         Biomedical Companies

·         Biotechnology Companies

·         Data Management Companies


Conferenceseries LLC cancer conferences invites all the participants from all over the world to attend ‘3rd World Gynecologic Oncology Congress’ during June 29-30, 2017 Baltimore, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Global Gynecology Oncology 2017 is a platform to discuss and learn about Cause of the cancer its Symptoms, Pathogenesis, Types, Tests, Screening, Diagnosis and Monitoring Gynecology Treatment, Surgical Methods, Prevention, clinical trials and research, Sexual and reproductive issues and Role of imaging in Gynecology Oncology conferences.

Track 1: Gynecologic Oncology

Oncology Gynecology is the study about any cancer that begins in a woman's reproductive organs. The five Gynecology cancers starts in the woman's pelvis at different places. Each cancer is unique by its symptoms, signs, risk factors and in their strategies of prevention. All these five different types of Gynecology Cancers risk increases with the age. When these cancers were diagnosed at their early stages, the treatment will be more efficient.The five major types of cancer affect a woman's reproductive organs are ovarian, uterine, cervical,vulvar, and vaginal cancerAll these as a group are known as Gynecology cancers 


Track 2: Breast Cancer

Breast cancer is the most common invasive Oncology Gynecology in females worldwide. It accounts for 16% of all female cancers and 22.9% of invasive cancers in women. 18.2% of all cancer deaths worldwide, including both males and females, are from breast cancer. Breast cancer rates are much higher in developed nations compared to developing ones. There are several reasons for this, with possibly life-expectancy being one of the key factors - breast cancer is more common in elderly women; women in the richest countries live much longer than those in the poorest nations. The different lifestyles and eating habits of females in rich and poor countries are also contributory factors, experts believe.


Track 3: Ovarian Cancer

Ovarian cancer is most common in Gynecology Cancers in women who have been through the menopause (usually over the age of 50), although it can affect women of any age.As the symptoms of ovarian cancer can be similar to those of other conditions, it can be difficult to recognise. However, there are early symptoms to look out for, such as persistent bloating, pain in the pelvis and lower stomach, and difficulty eating. The treatment you receive for ovarian cancer will depend on several things, including the stage of your cancer and your general health. Chemotherapy is the main treatment for ovarian cancer, but your treatment will usually involve a combination of surgery and chemotherapy.


Track 4: Endometrial Cancer

Endometrial cancer is a type of cancer that begins in the uterus. The uterus is the hollow, pear-shaped pelvic organ in women where fetal development occurs. Endometrial cancer is often detected at an early stage because it frequently produces abnormal vaginal bleeding, which prompts women to see their doctors. If endometrial cancer is discovered early, removing the uterus surgically often cures endometrial cancer. Endometrial cancer can spread to other parts of your body, making it more difficult to treat successfully. Endometrial cancer that spreads (metastasizes) most often travels to the lungs.


Track 5: Cervical Cancer

Cervical cancer is a type of cancer that develops in a woman's cervix (the entrance to the womb from the vagina).Cancer of the cervix often has no symptoms in its early stages. If you do have symptoms, the most common is unusual vaginal bleeding, which can occur after sex, in between periods or after the menopause. Almost all cases of cervical cancer are caused by the human papilloma virus (HPV). HPV is a very common virus that can be passed on through any type of sexual contact with a man or a woman. Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor.


Track 6: Uterine Cancer

Uterine cancer is the most common cancer of a woman’s reproductive system. Uterine cancer begins when normal cells in the uterus change and grow uncontrollably, forming a mass called a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can spread to other parts of the body. There are two major types of uterine cancer 1)Adenocarcinoma. This makes up more than 80% of uterine cancers. It develops from cells in the lining of the uterus called the endometrium. 2)Sarcoma type of uterine cancer develops in the supporting tissues of the uterine glands or in the myometrium, which is the uterine muscle.


Track 7: Vulvar/Vaginal cancer

Vulvar cancer is a rare type of  Oncology Gynecology cancer. It forms in a woman's external genitals, called the vulva. The cancer usually grows slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early. Radiation therapy may be used in more advanced vulvar cancer cases when disease has spread to the lymph nodes and/or pelvis. It may be performed before or after surgery. Women with vulvar cancer should have routine follow-up and exams with their oncologist, often every 3 months for the first 2–3 years after treatment. They should not have routine surveillance imaging to monitor the cancer unless new symptoms appear or tumor markers begin rising. Imaging without these indications is discouraged because it is unlikely to detect a recurrence or improve survival and is associated with its own side effects and financial costs.


Track 8: Cancer Drugs

The implementation of new drug treatments has improved the prognosis for advanced cancers of the cervix, uterus, and ovary. Platinum analogs are the most effective drugs in the treatment of ovarian cancer. Fertility drugs (FD) are spreading worldwide fast and therefore many studies have reviewed the possible association between the use of these drugs and cancer. Since the drugs used for ovulation induction during in vitro fertilization (IVF) like hCG, hMG, rFSH increase the levels of gonadal hormones, concerns have grown regarding the risk of developing cancer in breast, ovary, endometrium, and other target organs.If the treatment plan involves chemotherapy you may experience physical, emotional, and/or psychological side effects related to this treatment. The side effects of ovarian cancer treatment depend on the type of treatment and may be different for each woman


Track 9: Gynecologic Oncology: Pathogenesis

Gestational trophoblastic disease (GTD) is the general name for a group of rare tumors that occur during pregnancy in the fetalchorion, GTD can occur in any kind of pregnancy which is almost always curable if found early in Oncology Gynecology Pathogenesis. Uterine leiomyosarcoma (LMS) is a rare uterine malignancy it is an aggressive tumor associated with a high risk of recurrence and death, regardless of stage.Choriocarcinoma is a cancer that develops most commonly from abnormal placenta and it is nearly 100% curable if appropriate chemotherapy is administered after the tumor mass is separated from inside the uterus.


Track 10: Gynecologic Surgery 

In Oncology Gynecology the Gynecologic Surgical methods include- Initial Debulking surgery,   which may be performed by variety of procedures depending on the type & stage of ovarian cancer based on individual fertility concerns. The procedure for removal of ovary and fallopian tubes is known as Bilateral salpingo-oophorectomy surgery. The surgical removal of uterus and cervix is known as.Total hysterectomy. Lymph node biopsy will be performed by collecting the fluid sample from the abdomen. Omentectomy is surgical process for removing of omentum partially or as a whole. Fold of fatty tissue inside the abdomen is known as Omentum.  


Track 11: Role of imaging in Gynecologic Oncology

Oncology Gynecology the endometrial cancer, MRI is used to identify myometrial invasion and extrauterine disease, allowing preoperative surgical planning in women with serious comorbidity. In cervical cancer, MRI has an established role in local staging. By assessing the proximal extension of tumours in young women, MRI determines the feasibility of fertility-preserving surgery. It is also used to plan and administer radiotherapy. This optimises tumour radiation, while limiting unwanted radiation to the bowel and other pelvic organs.Gynecology Cancer the ovarian cancer, MRI is useful in young women as it is superior to ultrasound in diagnosing endometriomas, dermoids and fibroids, which can be misdiagnosed by ultrasound as malignant lesions.


Track 12: Clinical Gynecologic Oncology

The vast majority of the lesions that occur in the breast are benign. Much concern is given to malignant lesions of the breast because breast cancer is the most common malignancy in women in Western countries; however, benign lesions of the breast are far more frequent than malignant ones of Clinical Gynecologic Cancer.With the use of mammography, ultrasound, and magnetic resonance imaging of the breast and the extensive use of needle biopsies.Most importantly, a pregnant woman with cancer is capable of giving birth to a healthy baby because cancer rarely affects the fetus directly. Although some cancers may spread to the placenta, most cancers cannot spread to the baby. However, being pregnant with cancer is extremely complicated for both the mother and the health care team. Transfusion of one or more of the components of whole blood. The blood components may have been taken from the patient previously (autologous transfusion) or donated by someone else (homologous transfusion). Except in the case of acute hemorrhage, the transfusion of whole blood is rarely needed


Track 13Nursing and Health care

As the world becomes more complex and knowledge in every field becomes more extensive and detailed, it’s increasingly difficult to master everything in any one area. This is certainly true in the field of Gynecologists practice, which is undoubtedly one of the reasons for the recent trend towards specialization. However, this is only one of many factors contributing to the shift. Today, the multitude of pressures affecting Radiologists in general—and comprehensive Gynecologists in particular has become so oppressive that many doctors wonder whether comprehensive Gynecologists can survive.



Gynecologic Oncology 2016


Gynecologic Oncology 2016: Past Conference Report

The success of the Gynecology & Obstetrics conference has given us the prospect to bring the gathering one more time. Conferenceseries LLC hosted the “Experts Meeting on Gynecologic Oncology” during May 19-21, 2016 at Hilton San Antonio Airport Hotel, San Antonio, USA,

The conference was focused on Gynecologic Cancers and Breast cancer Research studies with the theme “Integrating the Milestones in Gynecologic Oncology Globally”. The meeting engrossed a vicinity of comprehensive discussions on novel subjects like ovarian cancer, Breast cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer.

The conference was embarked with an opening ceremony followed by Keynote sessions and followed by series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:


  • Dr. Sandra S. Hatch, The University of Texas Medical Branch, USA
  • Dr. Sherry Bradford, AccuTheranostics, Inc, USA
  • Dr. Hirendranath Banerjee, Elizabeth City State University, USA
  • Dr. Karl Reinhard Aigner, Medias Klinikum GmbH & Co KG, Germany
  • Mr. Adrian Senderowicz, CeruleanPharma, Inc., USA
  • Dr. Magdalena Klink, Polish Academy of Sciences, Poland


Best Poster Awardees:

Sean S. Jacob: University of Central Florida, USA

Alexis Barfield: USA

Dorothy Crumity: USA

Conferenceseries LLC offers its heartfelt appreciation to Organizing Committee Members, dexterous of field, various outside experts, company representatives and is obliged to other eminent personalities who interlaced with Conferenceseries LLC and supported the conference in every aspect, without which the conference would not have been possible.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Gynecologic Oncology 2016, Conferenceseries LLC would like to announce the commencement of the 3rd World Gynecologic Oncology Congress to be held during June 29-30, 2017 Baltimore, USA. We welcome all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of Gyneocology Research.


For More details:

Let us meet again @ Gynecologic Oncology 2017

Past Reports  Gallery  

Click here to submit abstract to any of the above topics


Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date June 29-30, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Media Partners

Conferenceseries Destinations